Effectiveness of Ivermectin and Doxycycline on COVID-19 Patients

Alkarkh Health Directorate-Baghdad

Status and phase: Completed; Phase 2; Phase 1

Conditions: Covid19

Treatments: Drug: Ivermectin and Doxycyline; Drug: Standard of care

Study type: Interventional

Funder types: Other

Identifiers

NCT04591600

IVM-DOX

Details and patient eligibility

About

A randomized controlled trial on using Ivermectin and doxycycline to treat mild-moderate outpatients, severe, and critical inpatients of Coronavirus disease 19 (COVID-19) along with standard of care. Seventy Iraqi COVID-19 patients received Ivermectin and Doxycycline plus standard of care versus seventy Iraqi COVID-19 patients received standard of care only. .

Full description

Objectives: COVID-19 patients suffer from the lack of curative therapy. Hence, there is an urgent need to try old re-purposed drugs on COVID-19. Methods: Randomized controlled study on 70 COVID-19 patients (48 mild-moderate, 11 severe, and 11 critical patients) treated with 200ug/kg PO of Ivermectin per day for 2 days along with 100mg PO doxycycline twice per day for 5-10 days plus standard therapy; the second arm is 70 COVID-19 patients (48 mild-moderate and 22 severe and zero critical patients) on standard therapy. The time to recovery, the progression of the disease, and the mortality rate were the outcome-assessing parameters.

Enrollment: 140 patients

Sex: All

Ages: 16 to 86 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• COVID-19 patients at any stage of this disease

Exclusion criteria

• Patients of allergic history to Ivermectin or to doxycyline

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Single Blind

---

140 participants in 2 patient groups

Ivermectin-Doxycycline

Experimental group

Description:

Ivermectin 200ug/kg PO per day for two days, and in some patients who needed more time to recover, a third dose 200ug/kg PO per day was given 7 days after the first dose. Doxycycline 100mg capsule PO every 12h per day was given for 5-10 days, based on the clinical improvement of patients. In addition, standard of care was given to the patients of Ivermectin-Doxycycline group based on the clinical condition of each patient.

Treatment:

Drug: Standard of care

Drug: Ivermectin and Doxycyline

Control

Active Comparator group

Description:

Control group: The patients in this group received only standard care which included all or some of the following, according to the clinical condition of each patient.

Treatment:

Drug: Standard of care